Viral Vector Infectivity Verification Using Flow Cytometry
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for manufacturing viral vector-based vaccines are inefficient, time-consuming, and costly, particularly in verifying the production of infectious viral particles.
Innovation Solution
A method involving ion-exchange based membrane purification of viral vectors from crude cell lysates, combined with rapid verification of virus infectivity using antibody-based detection and flow cytometry, allows for the production of neo-antigen vectors in less than 3 days.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional hexon-based detection assays are used to verify viral particle production, then detection accuracy is maintained, but the process becomes time-consuming and expensive
Solution Approach 1:
The patent replaces traditional mechanical/chemical detection assays with a biological assay system. Instead of using hexon-based detection methods that require extensive reagents and manual procedures, the invention employs a cell-based system where cells are transfected with reporter genes that produce detectable signals (such as luciferase or fluorescent proteins) upon viral infection. This biological substitution enables automated, high-throughput detection that is both rapid and accurate, resolving the contradiction between measurement precision and time consumption.
2Productivity
If rapid verification methods are implemented to reduce production time, then productivity increases, but manufacturing complexity increases
Solution Approach 1:
The patent segments the verification process into distinct modular components: (1) cell transfection with reporter genes, (2) viral infection step, and (3) signal detection step. Each module can be independently optimized and standardized. The use of automated liquid handling systems and pre-prepared reagent kits further segments the workflow, reducing manual intervention while maintaining rapid throughput. This modular segmentation enables rapid production without proportionally increasing overall system complexity.
Solution Approach 2:
The assay system is designed to be self-indicating through the use of reporter genes that automatically produce detectable signals upon viral infection. The cells themselves serve as both the target for viral infection and the detection platform, eliminating the need for separate complex detection apparatus. The viral particles carry their own detection marker (the reporter gene expression), making the system self-sufficient and reducing external complexity.
3Manufacturing precision
If extensive purification steps are used to ensure viral vector purity, then product quality is improved, but manufacturing time and cost increase
Solution Approach 1:
The patent extracts and removes unnecessary intermediate purification steps from the manufacturing process. By using the cell-based reporter assay that can detect and quantify infectious viral particles directly in crude lysates, the invention eliminates the need for multiple sequential purification and verification steps. The assay is designed to work with minimally processed samples, extracting only the essential detection function while discarding redundant purification operations that consume time and resources.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly reduces the time and cost of verifying infectious virion production, enabling efficient and scalable manufacturing of clinical-grade vaccines.
Implementation Method 1
introducing an ion-exchange based membrane method of purifying viral vectors from crude cell lysates
Implementation Method 2
measuring mass accumulation on the glass surface by bio-layer interferometry (BLI)
Implementation Method 3
performing flow cytometry and selecting for live, hexon-positive cells
Data Source
AI summary
Methods for rapidly confirming production of infectious viral vectors, for use in clinical grade personalized neo-antigen vaccines for subjects in need thereof, are provided.